Amgen reports 58 percent lower death risk in lung cancer study. What it means for Amgen stock

Published on 10/25/2026 at 17:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Amgen reported an October 24 lung cancer update. Amgen stock was EUR 392.10 at Lang & Schwarz at 5:21 p.m. CEST on October 25, 2026.

Weekend event and session dates

On October 24, Amgen reported a 58 percent reduction in death risk in a lung cancer study.
Amgen stock traded in weekend trading at Lang & Schwarz at EUR 392.10 at 5:21 p.m. CEST on October 25, 2026.
The next Xetra session is scheduled for October 26, 2026.

Pop-Art-Comic-Illustration eines Wissenschaftlers mit Spritze und Fläschchen vor buntem Halbton-Punktmuster — Amgen Inc. (ISIN US0311621009) präsentiert sich hier als farbenfrohe Pop-Art-Comic-Szene mit forschendem Laborwissenschaftler, Illustration mit AI erstellt.

Amgen reported on October 24 that IMDELLTRA in combination with IMFINZI reduced the risk of death by 58 percent in first-line extensive-stage small-cell lung cancer. The company published the update as a news release on its investor-relations website.

At 5:21 p.m. CEST on October 25, 2026, Amgen traded in weekend trading at Lang & Schwarz at EUR 392.10. Xetra and the primary exchanges were closed during the weekend-trading session.

The further course of weekend trading at Lang & Schwarz until 7:00 p.m. CET/CEST is shown by the continuously updated real-time quote of Amgen stock.

Market context: Market report S&P 500.

Company update

The October 24 release described findings from first-line extensive-stage small-cell lung cancer involving IMDELLTRA and IMFINZI. The release is available through Amgen Investor Relations.